Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.

doi:10.1182/blood-2018-02-829911

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.

Blood - 18 Oct 2018

Thol Felicitas, Gabdoulline Razif, Liebich Alessandro, Klement Piroska, Schiller Johannes, Kandziora Christian, Hambach Lothar, Stadler Michael, Koenecke Christian, Flintrop Madita, Pankratz Mira, Wichmann Martin, Neziri Blerina, Büttner Konstantin, Heida Bennet, Klesse Sabrina, Chaturvedi Anuhar, Kloos Arnold, Göhring Gudrun, Schlegelberger Brigitte, Gaidzik Verena I, Bullinger Lars, Fiedler Walter, Heim Albert, Hamwi Iyas, Eder Matthias, Krauter Jürgen, Schlenk Richard F, Paschka Peter, Döhner Konstanze, Döhner Hartmut, Ganser Arnold, Heuser Michael

Abstract excerpt

Molecular measurable residual disease (MRD) assessment is not established in approximately 60% of acute myeloid leukemia (AML) patients because of the lack of suitable markers for quantitative real-time polymerase chain reaction. To overcome this limitation, we established an error-corrected next-generation sequencing (NGS) MRD approach that can be applied to any somatic gene mutation. The clinical significance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Neoplasm Recurrence, Local

Share to Neoplasm, Residual

Share to Nucleophosmin

Share to Remission Induction

Share to Survival Rate

Share to Transplantation, Homologous

Source

Open in PubMed Open full text

Identifiers

PMID: 30190321
DOI: 10.1182/blood-2018-02-829911
PMCID: PMC7116653

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.PMID 30190321Read ↗

Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid LeukemiaSemantic proximity Read ↗

Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing.Semantic proximity Read ↗

Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.Semantic proximity Read ↗

Monitoring of measurable residual disease by next‐generation sequencing in patients with acute myeloid leukaemiaSemantic proximity Read ↗

Next‐generation sequencing for measurable residual disease detection in acute myeloid leukaemiaSemantic proximity Read ↗

NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemiaSemantic proximity Read ↗

Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaSemantic proximity Read ↗

Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations.Semantic proximity Read ↗

Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study.Semantic proximity Read ↗

Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AMLSemantic proximity Read ↗

Next-generation sequencing–based MRD in adults with ALL undergoing hematopoietic cell transplantationSemantic proximity Read ↗

Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.